Eric is a co‑founder of the French Myeloma Patients Association (AF3M), where he first became involved as a caregiver for his late father in 2007. He currently serves as Board Member and Head of International Relations. Eric brings over 40 years of experience in the financial sector, having led asset‑management sales across several European regions. He is committed to fostering the sharing of best practices among patient organisations and strengthening their collective efforts to serve the wider European myeloma community. Eric completed the MPE Advocate Development Programme, the WECAN Academy in 2025 and is a EUPATI HTA Ambassador.
EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for…